153 related articles for article (PubMed ID: 14720125)
1. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries.
Orlewska E; Mierzejewski P
Value Health; 2004; 7(1):1-10. PubMed ID: 14720125
[TBL] [Abstract][Full Text] [Related]
2. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
3. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada.
Marshall DA; Douglas PR; Drummond MF; Torrance GW; Macleod S; Manti O; Cheruvu L; Corvari R
Pharmacoeconomics; 2008; 26(6):477-95. PubMed ID: 18489199
[TBL] [Abstract][Full Text] [Related]
5. Budget impact analysis.
Leelahavarong P
J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
[TBL] [Abstract][Full Text] [Related]
6. The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA).
Ghabri S; Autin E; Poullié AI; Josselin JM
Pharmacoeconomics; 2018 Apr; 36(4):407-417. PubMed ID: 29247437
[TBL] [Abstract][Full Text] [Related]
7. [HAS budget impact analysis guidelines: A new decision-making tool].
Ghabri S; Poullié AI; Autin E; Josselin JM
Sante Publique; 2017 Oct; 29(4):585-588. PubMed ID: 29034674
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
9. Role of budget impact in drug reimbursement decisions.
Cohen JP; Stolk E; Niezen M
J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment in Poland and Scotland: comparison of process and decisions.
Kolasa K; Wasiak R
Int J Technol Assess Health Care; 2012 Jan; 28(1):70-6. PubMed ID: 22617739
[TBL] [Abstract][Full Text] [Related]
11. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
Adang E; Voordijk L; Jan van der Wilt G; Ament A
Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
[TBL] [Abstract][Full Text] [Related]
13. Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review.
Luo Z; Ruan Z; Yao D; Ung COL; Lai Y; Hu H
Front Public Health; 2021; 9():765999. PubMed ID: 34869180
[No Abstract] [Full Text] [Related]
14. Belgian guidelines for budget impact analyses.
Neyt M; Cleemput I; Sande SV; Thiry N;
Acta Clin Belg; 2015 Jun; 70(3):175-80. PubMed ID: 25579611
[TBL] [Abstract][Full Text] [Related]
15. Drug reimbursement decision-making in Thailand, China, and South Korea.
Ngorsuraches S; Meng W; Kim BY; Kulsomboon V
Value Health; 2012; 15(1 Suppl):S120-5. PubMed ID: 22265058
[TBL] [Abstract][Full Text] [Related]
16. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
[TBL] [Abstract][Full Text] [Related]
17. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities.
Hoffmann C; Stoykova BA; Nixon J; Glanville JM; Misso K; Drummond MF
Value Health; 2002; 5(2):71-8. PubMed ID: 11918822
[TBL] [Abstract][Full Text] [Related]
18. Estimating Downstream Budget Impacts in Implementation Research.
Wagner TH; Dopp AR; Gold HT
Med Decis Making; 2020 Nov; 40(8):968-977. PubMed ID: 32951506
[TBL] [Abstract][Full Text] [Related]
19. A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions.
Foroutan N; Tarride JE; Xie F; Levine M
Clinicoecon Outcomes Res; 2018; 10():821-854. PubMed ID: 30538513
[TBL] [Abstract][Full Text] [Related]
20. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
Delwel GO; Sprenger MJ
Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
